Active Not RecruitingNCT05905003
Official study titleAccelerating Medicines Partnership® Schizophrenia Observational Study: Psychosis Risk Evaluation, Data Integration, and Computational Technologies -Data Processing, Analysis, and Coordination Center and Coordination Center
This study is no longer accepting new participants.
Multiple locations, including IrvineSchizophreniaObservational studyAges 12–30
- Countries
- United States, Australia, Canada, + 10 others
- Sponsor
- Brigham and Women's Hospital
CompletedNCT00878462
Official study titleA Randomized, Crossover Study Evaluating the Acceptability of Unflavored Asenapine and Raspberry Flavored Asenapine in Stable Subjects With A Psychotic Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Organon and Co
CompletedNCT00526877
What is this study about?This study evaluated the safety and effectiveness of Risperidone for people with schizophrenia.
This study has finished and is no longer accepting participants.
In TaipeiSchizophreniaMedication studyAges 18+
- Countries
- Taiwan
- Sponsor
- Johnson & Johnson Taiwan Ltd
CompletedNCT02983188
Official study titleA Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders
This study has finished and is no longer accepting participants.
In TuenmenSchizophreniaMedication studyAges 18–65
- Countries
- China
- Sponsor
- The University of Hong Kong
CompletedNCT04949542
Official study titleDevelopment and Testing of a Caregiver-facing Mobile Health Intervention to Reduce Duration of Untreated Psychosis
This study has finished and is no longer accepting participants.
In SeattleSchizophreniaBehavioural studyAges 18–80
- Countries
- United States
- Sponsor
- University of Washington
Active Not RecruitingNCT05824728
Official study titleClinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
This study is no longer accepting new participants.
In BaltimoreSchizophreniaMedication studyAges 40–85
- Countries
- United States
- Sponsor
- Johns Hopkins University
Active Not RecruitingNCT06453174
This study is no longer accepting new participants.
In SalamancaSchizophreniaObservational studyAges 12–35
- Countries
- Spain
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
UnknownNCT05455593
Official study titleEfficacy of the Combination of Water Aerobics and Metacognitive Training (MCT) on Psychological and Physical Health Variables and Their Relationship With SP1 and SP4 Biomarkers in People With Psychosis
Current recruitment status is unconfirmed.
In Sant Boi de LlobregatSchizophreniaBehavioural studyAges 18–55
- Countries
- Spain
- Sponsor
- Fundació Sant Joan de Déu
CompletedNCT03649815
Official study titleTesting the Feasibility and Outcomes of a Digital Health Support for Individuals With Schizophrenia Spectrum Mental Illnesses
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaInterventional studyAges 18+
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
UnknownNCT06314204
Official study titleImpact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms : Multicenter Comparative Observational Study
Current recruitment status is unconfirmed.
In Neuilly-sur-MarneSchizophreniaObservational studyAges 18+
- Countries
- France
- Sponsor
- Centre hospitalier de Ville-Evrard, France
CompletedNCT03955549
Official study titleInsight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
This study has finished and is no longer accepting participants.
In ŢalkhāSchizophreniaMedication studyAges 18–65
- Countries
- Egypt
- Sponsor
- Agiad Psychiatry Hospital
Active Not RecruitingNCT02102113
This study is no longer accepting new participants.
In West HavenSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Yale University